NANJING TigerPharmatech Co., LTD.,

Nanjing Tiger Biopharmaceutical Co., Ltd. is a company engaged in organic synthesis and pharmaceutical intermediate synthesis. The company's general manager, Dr. Zhang Junhu, was born in January 1963. He has a Ph.D. in Chemistry from the University of Albertada in Canada. He studied under EJ Corey, a Nobel Prize winner at Harvard University. He once served as a postdoctoral researcher in the laboratory of a Nobel Prize winner in the Department of Biology and Chemistry of Harvard University, and the chief scientist of anti-cancer drug research and development of Pfizer Company in the United States. Dr. Zhang Junhu not only has profound knowledge in the field of medicinal chemistry, but also has high achievements in biology, pharmacology, drug metabolism and drug targets, as well as patent application and protection for new drug research and development. Won the Bio-Mega/Boehringer Ingelheim Award, the most important award in Canadian industry. In 2007, Dr. Zhang Junhu founded TigerPharmatech. The new c-Met target anti-cancer drug developed by the company is at the forefront of the world. The drug is approaching the first phase of clinical trials and has better performance than current clinical trial drugs, and has been protected by the world's new drug patent. In 2010, Gulou District and Nanjing University of Technology jointly introduced Dr. Zhang Junhu as a "leading industrial technology talent at home and abroad". Gulou District provided 3 million yuan (RMB) in support funds, and Nanjing University of Technology provided a 100-square-meter laboratory, professorships and research teams, etc. . Dr. Zhang Junhu came to Nanjing to start a business with a c-Met target anti-cancer drug project. In August 2010, he founded Nanjing Tiger Biopharmaceutical Co., Ltd. in Gulou District, which will fill the gap in the domestic industry and generate huge economic benefits. In 2011, he was selected into Nanjing’s “Zijin Talent Plan”.